Free Trial
NASDAQ:KPRX

Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

Kiora Pharmaceuticals logo
$3.62 -0.12 (-3.21%)
(As of 11/12/2024 ET)

About Kiora Pharmaceuticals Stock (NASDAQ:KPRX)

Key Stats

Today's Range
$3.61
$3.80
50-Day Range
$3.10
$4.04
52-Week Range
$3.00
$8.98
Volume
16,580 shs
Average Volume
74,278 shs
Market Capitalization
$10.75 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00
Consensus Rating
Strong Buy

Company Overview

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Kiora Pharmaceuticals Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
72nd Percentile Overall Score

KPRX MarketRank™: 

Kiora Pharmaceuticals scored higher than 72% of companies evaluated by MarketBeat, and ranked 323rd out of 986 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Kiora Pharmaceuticals has received a consensus rating of Strong Buy. The company's average rating score is 3.50, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Kiora Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Kiora Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Kiora Pharmaceuticals are expected to decrease in the coming year, from $1.17 to ($2.23) per share.

  • Price to Book Value per Share Ratio

    Kiora Pharmaceuticals has a P/B Ratio of 0.51. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Kiora Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    1.76% of the float of Kiora Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kiora Pharmaceuticals has recently increased by 1,197.22%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Kiora Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Kiora Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.76% of the float of Kiora Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Kiora Pharmaceuticals has a short interest ratio ("days to cover") of 1.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Kiora Pharmaceuticals has recently increased by 1,197.22%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Kiora Pharmaceuticals has a news sentiment score of 1.14. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 5 news articles for Kiora Pharmaceuticals this week, compared to 0 articles on an average week.
  • Search Interest

    Only 1 people have searched for KPRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Kiora Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,625.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 0.94% of the stock of Kiora Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    76.97% of the stock of Kiora Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Kiora Pharmaceuticals' insider trading history.
Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

KPRX Stock News Headlines

Watch this before it gets removed
If you missed it, my emergency election broadcast is now available - but will be removed soon
Kiora Pharmaceuticals Gains Approval for Phase 2 Trial
Kiora Pharmaceuticals Inc (7EY0.MU)
See More Headlines

KPRX Stock Analysis - Frequently Asked Questions

Kiora Pharmaceuticals' stock was trading at $4.7016 at the start of the year. Since then, KPRX shares have decreased by 23.0% and is now trading at $3.62.
View the best growth stocks for 2024 here
.

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) announced its earnings results on Friday, November, 8th. The company reported ($0.81) EPS for the quarter, beating analysts' consensus estimates of ($0.90) by $0.09.

Shares of Kiora Pharmaceuticals reverse split on Tuesday, June 11th 2024. The 1-9 reverse split was announced on Tuesday, June 11th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, June 11th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split.

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Kiora Pharmaceuticals investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/08/2024
Today
11/12/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
3/24/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KPRX
Fax
N/A
Employees
10
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+176.2%
Consensus Rating
Strong Buy
Rating Score (0-4)
3.50
Research Coverage
2 Analysts

Profitability

Net Income
$-12,510,000.00
Pretax Margin
20.54%

Debt

Sales & Book Value

Annual Sales
$16 million
Book Value
$7.14 per share

Miscellaneous

Free Float
2,942,000
Market Cap
$10.75 million
Optionable
Not Optionable
Beta
-0.29
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

This page (NASDAQ:KPRX) was last updated on 11/13/2024 by MarketBeat.com Staff
From Our Partners